BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Japanese Drugmakers Strengthen Area Ties


10/19/2005 5:13:10 PM

Japanese drugmakers are keeping their roots firmly planted in the Chicago area. Effective Friday, Astellas Pharma U.S. Inc. will list the address of its U.S. headquarters as Deerfield, the longtime home of Fujisawa Healthcare Inc. The Astellas name replaces Fujisawa as a result of Fujisawa's recently completed merger with Yamanouchi Pharmaceutical Co. of Tokyo. Yamanouchi's U.S. headquarters had been in New Jersey but will now be in Deerfield. Under the Astellas name, the combined Fujisawa-Yamanouchi operation has annual worldwide sales of about $8 billion, putting the company among the top 20 drugmakers in the world. "As Astellas, we will build on nearly two centuries of collective experience to create a unique place in the U.S. pharmaceutical landscape, where true innovation is valued and rewarded," said Makoto Nishimura, chairman and chief executive of Astellas Pharma U.S. Inc. In Japan, Astellas is second only to Takeda Pharmaceutical Co., which has more than $10 billion in annual worldwide sales. Like Astellas, Takeda has its U.S. base here, with offices in suburban Lincolnshire under the name Takeda Pharmaceuticals North America Inc. Takeda also owns half of Lake Forest-based TAP Pharmaceutical Products Inc., with partner Abbott Laboratories. The United States has long been an important market for Japanese drugmakers, especially since there are no price controls in the U.S. as there are in their country, so selling drugs is more profitable here.

Read at Chicago Tribune

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES